The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Por:
Jimenez-Fonseca P., Foy V., Raby S., Carmona-Bayonas A., Macía-Rivas L., Arrazubi V., Cacho Lavin D., Hernandez San Gil R., Custodio A., Cano J.M., Fernández Montes A., Mirallas O., Macias Declara I., Vidal Tocino R., Visa L., Limón M.L., Pimentel P., Martínez Lago N., Sauri T., Martín Richard M., Mangas M., Gil Raga M., Calvo A., Reguera P., Granja M., Martín Carnicero A., Hernández Pérez C., Cerdá P., Gomez Gonzalez L., Garcia Navalon F., Pacheco Barcia V., Gutierrez Abad D., Ruiz Martín M., Weaver J., Mansoor W., Gallego J.
Publicada:
1 ene 2023
Ahead of Print:
4 mar 2023
Resumen:
BACKGROUND: Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with trastuzumab. METHODS: Patients with HER2-positive advanced gastro-oesophageal adenocarcinoma (AGA) from the Spanish Society of Medical Oncology (SEOM)-AGAMENON registry and treated first line with trastuzumab and chemotherapy between 2008 and 2021 were included. The model was externally validated in an independent series (The Christie NHS Foundation Trust, Manchester, UK). RESULTS: In all, 737 patients were recruited (AGAMENON-SEOM, n = 654; Manchester, n = 83). Median PFS and OS in the training cohort were 7.76 [95% confidence interval (CI), 7.13-8.25] and 14.0 months (95% CI, 13.0-14.9), respectively. Six covariates were significantly associated with OS: neutrophil-to-lymphocyte ratio, Eastern Cooperative Oncology Group performance status, Lauren subtype, HER2 expression, histological grade and tumour burden. The AGAMENON-HER2 model demonstrated adequate calibration and fair discriminatory ability with a c-index for corrected PFS/OS of 0.606 (95% CI, 0.578-0.636) and 0.623 (95% CI, 0.594-0.655), respectively. In the validation cohort, the model is well calibrated, with a c-index of 0.650 and 0.683 for PFS and OS, respectively. CONCLUSION: The AGAMENON-HER2 prognostic tool stratifies HER2-positive AGA patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints.
Filiaciones:
Jimenez-Fonseca P.:
Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain
Foy V.:
Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom
Raby S.:
Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom
Carmona-Bayonas A.:
Medical Oncology Department, Hospital Universitario Morales Meseguer, Calle Marqués de los Vélez, s/n, Murcia, 30007, Spain
Macía-Rivas L.:
Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain
Arrazubi V.:
Medical Oncology Department, Complejo Hospitalario de Navarra, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain
Cacho Lavin D.:
Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Hernandez San Gil R.:
Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain
Custodio A.:
Medical Oncology Department, Hospital Universitario La Paz, CIBERONC CB16/12/00398, Madrid, Spain
Cano J.M.:
Medical Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
Fernández Montes A.:
Medical Oncology Department, Complejo Hospitalario de Orense, Orense, Spain
Mirallas O.:
Medical Oncology Department, Hospital Universitario Vall d’Hebron, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain
Macias Declara I.:
Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain
Vidal Tocino R.:
Medical Oncology Department, Complejo Asistencial Universitario de Salamanca-IBSAL, Salamanca, Spain
Visa L.:
Medical Oncology Department, Hospital Universitario El Mar, Barcelona, Spain
Limón M.L.:
Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
Pimentel P.:
Medical Oncology Department, Hospital General Universitario Santa Lucía, Cartagena, Spain
Martínez Lago N.:
Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain
Sauri T.:
Medical Oncology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain
Martín Richard M.:
Medical Oncology Department, Catalan Institute of Oncology, Barcelona, Spain
Mangas M.:
Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain
Gil Raga M.:
Medical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain
Calvo A.:
Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
Reguera P.:
Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
Granja M.:
Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain
Martín Carnicero A.:
Medical Oncology Department, Hospital San Pedro, Logroño, Spain
Hernández Pérez C.:
Medical Oncology Department, Hospital Universitario Nuestra Señora de the Candelaria, Santa Cruz de Tenerife, Spain
Cerdá P.:
Medical Oncology Department, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain
Gomez Gonzalez L.:
Medical Oncology Department, Hospital General Universitario de Alicante, Alicante, Spain
Garcia Navalon F.:
Medical Oncology Department, Hospital Universitario Son Llatzer, Mallorca, Spain
Pacheco Barcia V.:
Medical Oncology Department, Hospital Universitario de Torrejón, Madrid, Spain
Gutierrez Abad D.:
Medical Oncology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain
Ruiz Martín M.:
Medical Oncology Department, Hospital Universitario Rio Carrión de Zamora, Zamora, Spain
Weaver J.:
Department of Medical Oncology, Christie Hospital/University of Manchester, Manchester, United Kingdom
Mansoor W.:
Department of Medical Oncology, Christie Hospital/University of Manchester, Manchester, United Kingdom
Gallego J.:
Medical Oncology Department, Hospital General Universitario of Elche, Elche, Spain
gold, Green Published, All Open Access, Gold, Green
|